Pacira BioSciences (PCRX) Net Income towards Common Stockholders (2010 - 2026)

Pacira BioSciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 39.4% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $5.1 million (up 104.95% YoY), while the FY2025 annual figure was $7.0 million, up 107.07% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $2.9 million, up from $1.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $25.8 million in Q2 2023, with the low at -$143.5 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is $5.4 million (2025), against an average of -$1.9 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 1666.81% in 2023, then sank 1421.29% in 2024.
• Pacira BioSciences' Net Income towards Common Stockholders stood at -$10.1 million in 2022, then surged by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then sank by 89.79% to $1.6 million in 2025, then surged by 78.13% to $2.9 million in 2026.
• Business Quant data shows PCRX's Net Income towards Common Stockholders at $2.9 million in Q1 2026, $1.6 million in Q4 2025, and $5.4 million in Q3 2025.